1. Home
  2. GNPX

as of 03-10-2026 3:59pm EST

$2.00
+$0.05
+2.49%
Stocks Health Care Biotechnology: Pharmaceutical Preparations Nasdaq

Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC.

Founded: 2009 Country:
United States
United States
Employees: N/A City: AUSTIN
Market Cap: 6.4M IPO Year: 2017
Target Price: N/A AVG Volume (30 days): 852.6K
Analyst Decision: N/A Number of Analysts: N/A
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -23.00 EPS Growth: 76.33
52 Week Low/High: $0.14 - $12.97 Next Earning Date: N/A
Revenue: N/A Revenue Growth: N/A
Revenue Growth (this year): N/A Revenue Growth (next year): N/A
P/E Ratio: -0.08 Index: N/A
Free Cash Flow: -17149088.0 FCF Growth: N/A

Share on Social Networks: